Genovis AB (publ.) (STO:GENO)

Market Cap	1.70B
Revenue (ttm)	123.87M
Net Income (ttm)	23.63M
Shares Out	65.47M
EPS (ttm)	0.36
PE Ratio	72.03
Forward PE	54.74
Dividend	n/a
Ex-Dividend Date	n/a

Volume	35,050
Average Volume	169,826
Open	25.90
Previous Close	26.00
Day's Range	25.85 - 26.80
52-Week Range	17.10 - 31.25
Beta	1.91
RSI	58.77
Earnings Date	Aug 12, 2025

About Genovis AB (publ.)

Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOUS (SpeB), a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. It also offers GlySERIAS, an enzyme that digests flexible glycine-rich fusion protein linkers; GlyCLICK, a conjugation technology; TransGLYCIT, a platform technology; and GingisRE...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 32
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: GENO

Financial Performance

In 2024, Genovis AB (publ.)'s revenue was 131.32 million, a decrease of -17.44% compared to the previous year's 159.07 million. Earnings were 32.92 million, a decrease of -46.48%.